• 제목
  • Korea Ministry of Food and Drug Safety R&D Webzine COVID-19 Special Issue

  • Registration date
  • 2020-08-27
  • 최종수정

The food and drug R&D webzine_Volume 8 issued by the Korea Food and Drug Administration was a special issue of COVID-19.

It consisted of an overview of COVID-19, vaccine development status, treatment development status, quarantine status and support programs, and expert contributions. Repure Life Science will also be named and introduced.

Coronavirus-19. After the first patient outbreak in Korea (2020.1.20), it has increased rapidly, mainly in Daegu and Gyeongbuk, but recently, it has increased rapidly in the Seoul metropolitan area.

There was also a development using a malaria treatment and AIDS treatment as a treatment for COVID-19, but it was discontinued, and only remdesivir was urgently approved, and the drug was started mainly for severely ill patients in Korea, but the effect on it is still to be observed because it is literally urgent approval.

The government is supporting the activation of new drug re-creation research and approval from the Ministry of Food and Drug Safety to reconsider existing treatments or candidates for new drugs for the development of COVID-19 treatment. In the case of vaccine development, it is being promoted mainly by domestic bio-ventures and vaccine development companies, but it is expected that it will take a considerable amount of time to commercialize the coronavirus as mutations continue to occur.

Therefore, it can be said that the development of effective therapeutic agents is more realistic in the present difficult and urgent situation.

 A total of nine companies, including Repure Life Science, are under development for a new drug treatment for COVID-19 in Korea, and there are no companies that have entered the forest stage right away, but companies that have entered the COVID-19 are predicted to come out soon, according to the COVID-19 special issue.

Source: R&D Webzine Corona 19 Special Issue / 2020 Volume 8 Pages 18-19

The Korean government has invested 210 billion won in the development of COVID-19 treatments and vaccines, and announced the deregulation of clinical trial procedures to increase competitiveness. The leaders of 30 countries around the world also announced support worth 10 trillion won, promising an international response.

There are 120 common infectious diseases that are the cause of most of the new viruses.

Repure Life Science, Yonsei Medical Center, and Kyungnam Biopharma are joint research efforts to detect neutralizing antibodies in the plasma of the cure and treat patients infected with COVID-19. Repure Life Science is a research project with artificial intelligence in accordance with the era of the 4th industrial revolution. It is in charge of screening candidates for COVID-19 treatment using big data.